|
1
|
Rao Krishna SV, Mejia G, Roberts-Thomson K
and Logan R: Epidemiology of oral cancer in Asia in the past
decade-an update (2000–2012). Asian Pac J Cancer Prev.
14:5567–5577. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Petersen PE: Oral cancer prevention and
control-the approach of the World Health Organization. Oral Oncol.
45:454–460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zini A, Czerninski R and Sgan-Cohen HD:
Oral cancer over four decades: Epidemiology, trends, histology, and
survival by anatomical sites. J Oral Pathol Med. 39:299–305. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liao G, Wang Y, Zhou YQ, Li TW, Zeng DQ,
Zeng X, Li J, Dan HX and Chen QM: Host genetic susceptibility to
oral cancer: Evidence from meta-analyses and pooled analyses. Oral
Dis. 20:644–649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bond GL, Hu W, Bond EE, Robins H, Lutzker
SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al: A
single nucleotide polymorphism in the MDM2 promoter attenuates the
p53 tumor suppressor pathway and accelerates tumor formation in
humans. Cell. 119:591–602. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bond GL, Hu W and Levine A: A single
nucleotide polymorphism in the MDM2 gene: From a molecular and
cellular explanation to clinical effect. Cancer Res. 65:5481–5484.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wo X, Han D, Sun H, Liu Y, Meng X, Bai J,
Chen F, Yu Y, Jin Y and Fu S: MDM2 SNP309 contributes to tumor
susceptibility: A meta-analysis. J Genet Genomics. 38:341–350.
2011.PubMed/NCBI
|
|
8
|
Chen B, Cao L, Hu KW, Zhang JW, Meng XL
and Xiong MM: MDM2 SNP309 is an ethnicity-dependent risk factor for
digestive tract cancers. Tumour Biol. 35:3431–3438. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tu HF, Chen HW, Kao SY, Lin SC, Liu CJ and
Chang KW: MDM2 SNP 309 and p53 codon 72 polymorphisms are
associated with the outcome of oral carcinoma patients receiving
postoperative irradiation. Radiother Oncol. 87:243–252. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang SF, Chen IH, Liao CT, Wang HM, Liou
SH and Hsieh LL: Combined effects of MDM2 SNP 309 and p53 mutation
on oral squamous cell carcinomas associated with areca quid
chewing. Oral Oncol. 45:16–22. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Misra C, Majumder M, Bajaj S, Ghosh S, Roy
B and Roychoudhury S: Polymorphisms at p53, p73, and MDM2 loci
modulate the risk of tobacco associated leukoplakia and oral
cancer. Mol Carcinog. 48:790–800. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hamid S, Yang YH, Peng KN, Ismail SM, Zain
RB, Lim KP, Wan Mustafa WM, Abraham MT, Teo SH and Cheong SC: MDM2
SNP309 does not confer an increased risk to oral squamous cell
carcinoma but may modulate the age of disease onset. Oral Oncol.
45:496–500. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen X, Sturgis EM, Lei D, Dahlstrom K,
Wei Q and Li G: Human papillomavirus seropositivity synergizes with
MDM2 variants to increase the risk of oral squamous cell carcinoma.
Cancer Res. 70:7199–7208. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Canova C, Hashibe M, Simonato L, Nelis M,
Metspalu A, Lagiou P, Trichopoulos D, Ahrens W, Pigeot I, Merletti
F, et al: Genetic associations of 115 polymorphisms with cancers of
the upper aerodigestive tract across 10 European countries: The
ARCAGE project. Cancer Res. 69:2956–2965. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Z, Sturgis EM, Zhang Y, Huang Z, Zhou
Q, Wei Q and Li G: Combined p53-related genetic variants together
with HPV infection increase oral cancer risk. Int J Cancer.
131:E251–E258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Y, Li S, Xiao HQ, Hu ZX, Xu YC and
Huang Q: Vascular endothelial growth factor gene polymorphisms and
renal cell carcinoma: A systematic review and meta-analysis. Oncol
Lett. 6:1068–1078. 2013.PubMed/NCBI
|
|
17
|
Wang JG, Zhang Y and Xiao TL: Quantitative
analysis of the association between CRP rs2808630 and rs1417938
polymorphisms and cancer risk. Oncol Lett. 9:994–998.
2015.PubMed/NCBI
|
|
18
|
Jiang LL and Ruan LW: Association between
FOXP3 promoter polymorphisms and cancer risk: A meta-analysis.
Oncol Lett. 8:2795–2799. 2014.PubMed/NCBI
|
|
19
|
Chen T, Yi SH, Liu XY and Liu ZG:
Meta-analysis of associations between the MDM2-T309G polymorphism
and prostate cancer risk. Asian Pac J Cancer Prev. 13:4327–4330.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu G, Jiang D, Shen S and Yu L: Murine
double minute 2 promoter SNP309 polymorphism and prostate cancer
risk: A meta-analysis. Int J Urol. 19:914–920. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ma YY, Guan TP, Yao HB, Yu S, Chen LG, Xia
YJ, He XJ, Wang HJ, Jiang XT and Tao HQ: The MDM2 309T>G
polymorphism and ovarian cancer risk: A meta-analysis of 1534 cases
and 2211 controls. PLoS One. 8:e550192013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Manfredi JJ: The Mdm2-p53 relationship
evolves: Mdm2 swings both ways as an oncogene and a tumor
suppressor. Genes Dev. 24:1580–1589. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Francis G, Dileep Kumar U, Nalinakumari
KR, Jayasree K and Kannan S: Accumulation of inactive p53 protein
in oral squamous cell carcinoma: Stabilization by protein
interaction. Eur J Oral Sci. 121:21–28. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Millon R, Muller D, Schultz I, Salvi R,
Ghnassia JP, Frebourg T, Wasylyk B and Abecassis J: Loss of MDM2
expression in human head and neck squamous cell carcinomas and
clinical significance. Oral Oncol. 37:620–631. 2001. View Article : Google Scholar : PubMed/NCBI
|
